Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction
In Vivo · 2025
DOI: 10.21873/invivo.14118 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Cheng-Hsi Liao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Predisposition to Disease, Cyclin-Dependent Kinase Inhibitor p21, Genotype. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Prostate cancer is a multifactorial disease influenced by both genetic and environmental factors. Previous studies have identified a correlation between p21 expression and the clinical severity of prostate cancer. However, the contribution of cyclin-dependent kinase inhibitor 1A (CDKN1A), which encodes p21, to prostate cancer susceptibility remains unclear. This study aimed to evaluate the association between CDKN1A polymorphisms rs1801270 and rs1059234 and the risk of prostate cancer in a Taiwanese population. PATIENTS AND METHODS: A total of 218 patients with prostate cancer and 436 cancer-free controls were genotyped for CDKN1A rs1801270 and rs1059234 using the PCR-RFLP method. Genotypic distributions were analyzed for associations with prostate cancer risk overall and stratified by age and smoking status. RESULTS: No significant association was observed between either CDKN1A rs1801270 or rs1059234 genotypes and overall prostate cancer risk (both p>0.05). However, stratified analysis showed that individuals aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
- Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
- Division of Urology, Department of Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- National Defense Medical University, Taipei, Taiwan, R.O.C.
- Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
- Department of Nephrology, Chang-Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan, R.O.C.
Zitieren
APA
Liao, C. H., Bau, D. T., Wang, B. R., Chang, S. Y., Hsia, T. C., Lee, H. T., Chen, J. C., Huang, W. C., Tsai, C. W., Wang, Y. C., Shih, H. Y., & Chang, W. S. (2025). Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction. In Vivo. https://doi.org/10.21873/invivo.14118
Vancouver
Liao CH, Bau DT, Wang BR, Chang SY, Hsia TC, Lee HT, et al. Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction. In Vivo. 2025. doi:10.21873/invivo.14118
BibTeX
@article{Liao2025,
author = {Liao, Cheng-Hsi and Bau, DA-Tian and Wang, Bo-Ren and Chang, Shu-Yu and Hsia, Te-Chun and Lee, Hsu-Tung and Chen, Jaw-Chyun and Huang, Wen-Chin and Tsai, Chia-Wen and Wang, Yun-Chi and Shih, Hou-Yu and Chang, Wen-Shin},
title = {Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14118}
}
EUVIMED